Keeping you up to date on recent developments in diagnostics, including: Brain imaging reveals signs of childhood trauma; Buyer beware for SARS-CoV-2 antibody detection; Tumor-associated cell cluster signal cancer alert.
With phase III vaccine trials nearly enrolled and data expected soon, a half-year of expedited development efforts, plus massive government funding may soon provide the ammunition needed to effectively stop the SARS-CoV-2 scourge of 2020.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Becton Dickinson, Genetron, Ka Imaging, Perkinelmer, Sentiar, Vexos.
CAJICA, Colombia – Privately held Inosan Biopharma SA De Cv, of Mexico City, is racing to develop a biological treatment to cure COVID-19 patients. Inosan has mastered the technique of using horses to produce antibodies to heal patients bitten by poisonous creatures, such as snakes, spiders and scorpions.
PERTH, Australia – Brandon Capital announced the launch of Ena Respiratory Pty Ltd., which has developed a nasal treatment to boost the natural immune system to fight common colds and flu and has proved successful in reducing COVID-19 viral replication.
LONDON – Oxford Immunotec plc is aiming to plug a significant gap in the COVID-19 diagnostics landscape, with the development of a commercial clinical grade test for quantifying T cell responses to the SARS-CoV-2 virus. T-Spot Discovery SARS-CoV-2, currently available for research use only, is based on the same automated technology as the company’s tuberculosis diagnostic, which is approved for use in more than 60 countries.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cepheid, Conformis, Guide Sensmart, Oxford Immunotec, Surgical Innovation Associates.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accelerate Technologies, Aptorum Group, Billiontoone, Confirm Biosciences, Exagen, Genosity, Infirmary Health, Inflammatix, Karl Storz, Labcorp, LC-SCRUM-Asia, Jellagen, Mayo Clinic, Olink Proteomics, Premier, Proterixbio, Provider Network of America, Pulse Biosciences, Radiant Technologies, Saranas, Securiport, Seek Thermal, Stryker, Swift Biosciences, Wright Medical, Thermo Fisher Scientific, Well Health Technologies.
PERTH, Australia – Australia’s largest health care venture capital firm, Brandon Capital, announced the launch of Australian biotech company Ena Respiratory Pty Ltd., which has developed a nasal treatment to boost the natural immune system to fight common colds and flu and has proved successful in reducing COVID-19 viral replication.
